Literature DB >> 11447155

Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

A Al-Mariri1, A Tibor, P Mertens, X De Bolle, P Michel, J Godefroid, K Walravens, J J Letesson.   

Abstract

The P39 and the bacterioferrin (BFR) antigens of Brucella melitensis 16M were previously identified as T dominant antigens able to induce both delayed-type hypersensivity in sensitized guinea pigs and in vitro gamma interferon (IFN-gamma) production by peripheral blood mononuclear cells from infected cattle. Here, we analyzed the potential for these antigens to function as a subunitary vaccine against Brucella abortus infection in BALB/c mice, and we characterized the humoral and cellular immune responses induced. Mice were injected with each of the recombinant proteins alone or adjuvanted with either CpG oligodeoxynucleotides (CpG ODN) or non-CpG ODN. Mice immunized with the recombinant antigens with CpG ODN were the only group demonstrating both significant IFN-gamma production and T-cell proliferation in response to either Brucella extract or to the respective antigen. The same conclusion holds true for the antibody response, which was only demonstrated in mice immunized with recombinant antigens mixed with CpG ODN. The antibody titers (both immunoglobulin G1 [IgG1] and IgG2a) induced by P39 immunization were higher than the titers induced by BFR (only IgG2a). Using a B. abortus 544 challenge, the level of protection was analyzed and compared to the protection conferred by one immunization with the vaccine strain B19. Immunization with P39 and CpG ODN gave a level of protection comparable to the one conferred by B19 at 4 weeks postchallenge, and the mice were still significantly protected at 8 weeks postchallenge, although to a lesser extent than the B19-vaccinated group. Intriguingly, no protection was detected after BFR vaccination. All other groups did not demonstrate any protection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11447155      PMCID: PMC98569          DOI: 10.1128/IAI.69.8.4816-4822.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  59 in total

1.  Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

Authors:  M Roman; E Martin-Orozco; J S Goodman; M D Nguyen; Y Sato; A Ronaghy; R S Kornbluth; D D Richman; D A Carson; E Raz
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

2.  CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.

Authors:  S Zimmermann; O Egeter; S Hausmann; G B Lipford; M Röcken; H Wagner; K Heeg
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

Review 3.  Recent advances in brucellosis.

Authors:  M J Corbel
Journal:  J Med Microbiol       Date:  1997-02       Impact factor: 2.472

Review 4.  Cytokines acting on or secreted by macrophages during intracellular infection (IL-10, IL-12, IFN-gamma).

Authors:  G Trinchieri
Journal:  Curr Opin Immunol       Date:  1997-02       Impact factor: 7.486

5.  Humoral immune responses of Brucella-infected cattle, sheep, and goats to eight purified recombinant Brucella proteins in an indirect enzyme-linked immunosorbent assay.

Authors:  J J Letesson; A Tibor; G van Eynde; V Wansard; V Weynants; P Denoel; E Saman
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

6.  Identification of the major T-cell antigens present in the Brucella melitensis B115 protein preparation, Brucellergene OCB.

Authors:  P A Denoel; T K Vo; V E Weynants; A Tibor; D Gilson; M S Zygmunt; J N Limet; J J Letesson
Journal:  J Med Microbiol       Date:  1997-09       Impact factor: 2.472

Review 7.  T lymphocyte mediated protection against facultative intracellular bacteria.

Authors:  G Splitter; S Oliveira; M Carey; C Miller; J Ko; J Covert
Journal:  Vet Immunol Immunopathol       Date:  1996-11       Impact factor: 2.046

8.  CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.

Authors:  A M Krieg; L Love-Homan; A K Yi; J T Harty
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

Review 9.  Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination.

Authors:  D A Carson; E Raz
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

10.  CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.

Authors:  R S Chu; O S Targoni; A M Krieg; P V Lehmann; C V Harding
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

View more
  38 in total

1.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

2.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of Brucella abortus in BALB/c mice.

Authors:  Shailendra Kumar Verma; Shikha Jain; Subodh Kumar
Journal:  World J Microbiol Biotechnol       Date:  2012-04-22       Impact factor: 3.312

4.  Induction of immune response in BALB/c mice with a DNA vaccine encoding bacterioferritin or P39 of Brucella spp.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godfroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.

Authors:  Apurba K Bhattacharjee; Mina J Izadjoo; Wendell D Zollinger; Mikeljon P Nikolich; David L Hoover
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria.

Authors:  M Victoria Delpino; Silvia M Estein; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Protection of mice against Brucella abortus 544 challenge by vaccination with recombinant OMP28 adjuvanted with CpG oligonucleotides.

Authors:  Purushottam Kaushik; Dhirendra K Singh; S Vinoth Kumar; Ashok K Tiwari; Gunjan Shukla; Shanker Dayal; Pallav Chaudhuri
Journal:  Vet Res Commun       Date:  2009-12-16       Impact factor: 2.459

9.  Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.

Authors:  Karina A Pasquevich; Silvia M Estein; Clara García Samartino; Clara García Samartino; Astrid Zwerdling; Lorena M Coria; Paula Barrionuevo; Carlos A Fossati; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  Discordant Brucella melitensis antigens yield cognate CD8+ T cells in vivo.

Authors:  Marina A Durward; Jerome Harms; Diogo M Magnani; Linda Eskra; Gary A Splitter
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.